Received Jul 8, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 5S723 | IM / RA |
meningitis-B component was administered to the patient intramuscularly, but the lyophilized meningitis-ACWY component was not administer to the patient/Misadministration; meningitis-B component was administered to the patient intramuscularly, but the lyophilized meningitis-ACWY component was not administer to the patient/Misadministration; This non-serious case was reported by a physician via sales rep and described the occurrence of inappropriate preparation of medication in a 16-year-old male patient who received Men ABCWY NVS (Penmenvy) suspension for injection in pre-filled syringe (batch number 5S723 with expiry date 08-OCT-2026) for prophylaxis. On 02-JUL-2026, the patient received the 1st dose of Penmenvy (intramuscular, right deltoid). On 02-JUL-2026, an unknown time after receiving Penmenvy, the patient experienced inappropriate preparation of medication (Verbatim: meningitis-B component was administered to the patient intramuscularly, but the lyophilized meningitis-ACWY component was not administer to the patient/Misadministration) and inappropriate dose of vaccine administered (Verbatim: meningitis-B component was administered to the patient intramuscularly, but the lyophilized meningitis-ACWY component was not administer to the patient/Misadministration). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.